|
|
|
After going through a number of false starts over the last decade, inhaled insulin could soon become an alternative option to meal time injections of the hormone.
The previous attempt by a large healthcare company, Pfizer, to introduce an inhaled insulin, Exubera, enjoyed only limited success.
Whilst the product worked relatively well, the inhaler was large and awkward to use and the cost of the insulin was too high.
More recent developments, however, have been more positive, with inhaled insulin manufacturers appearing to learn from these early mistakes. |
|
|
|
|
|
Afrezza is the name of the newest form of inhaled insulin to receive approval for use in the USA. People in the UK will need to keep holding their breath, so to speak, as the insulin is yet to gain regulatory approval.
However, there is promise that the insulin could become available outside of America as the pharmaceutical firm Sanofi recently purchased the rights to market Afrezza in a megadeal worth up to $925 million.
|
|
|
|
|
|
On the subject of breathing, diabetes is associated with modestly increased risks of suffering from certain breathing problems.
There are a range of conditions that can affect the lungs, each with a different cause and therefore different treatment.
Read more about the lung conditions which are more common in people with diabetes. |
|
|
|
|
|
.jpg)
